Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide

অনুরূপ উপাদানগুলি

• MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
  অনুযায়ী: Nachtigall, Lisa B, অন্যান্য
  প্রকাশিত: (2020)
• MON-314 Analysis of Adverse Events in Adult Patients with Acromegaly Receiving Oral Octreotide Capsules: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
  অনুযায়ী: Labadzhyan, Artak, অন্যান্য
  প্রকাশিত: (2020)
• MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
  অনুযায়ী: Nachtigall, Lisa B, অন্যান্য
  প্রকাশিত: (2020)
• One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly
  অনুযায়ী: Samson, Susan Leanne, অন্যান্য
  প্রকাশিত: (2021)
• Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
  অনুযায়ী: Gordon, Murray B, অন্যান্য
  প্রকাশিত: (2021)